RKDA — Arcadia Biosciences Cashflow Statement
0.000.00%
- $4.72m
- $0.48m
- $5.05m
Annual cashflow statement for Arcadia Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -6.03 | -16.1 | -15.6 | -14 | -7.04 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | -12.4 | -6.52 | 1.04 | 1.91 | -1.26 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -12.4 | -4.26 | 0.118 | -3.51 | -1.45 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -30.2 | -25.9 | -14 | -15.3 | -9.63 |
Capital Expenditures | -2.33 | -1.01 | -0.072 | -0.005 | -0.016 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 19.6 | 17.6 | 1.49 | -4.34 | 7.36 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 17.3 | 16.6 | 1.42 | -4.34 | 7.34 |
Financing Cash Flow Items | 0.063 | -1.16 | -0.488 | -0.497 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 20.6 | 21.9 | 4.52 | 5.51 | 0.009 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 7.63 | 12.6 | -8.04 | -14.1 | -2.28 |